ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
miR-214-3p and NCKAP1: A microglial functional dimension of Alzheimer's progression.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionBiological Alzheimer's disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient-derived induced microglia-like cell (iMG) profiles capture a functional dimension of AD progression beyond conventional plasma biomarkers.
methodsWe studied 114 participants comprising amyloid-negative healthy controls (n = 18) and amyloid-positive AD-continuum groups (cognitively unimpaired, n = 2; mild cognitive impairment, n = 18; AD dementia, n = 76). Plasma biomarkers, patient-derived iMG phagocytic function, and molecular markers were measured from the same blood draw. Longitudinal clinical follow-up was available in 102 participants, and paired baseline/follow-up blood samples were analyzed in a longitudinal biomarker cohort (n = 38).
resultsiMG phagocytic capacity progressively declined across the AD continuum, accompanied by reduced NCK-associated protein 1 (NCKAP1) expression and the strongest association with plasma glial fibrillary acidic protein (GFAP). Baseline NCKAP1 primarily reflected current cognitive impairment, whereas plasma miR-214-3p independently predicted faster cognitive decline beyond plasma tau phosphorylated at threonine 217 (p-tau217), GFAP, neurofilament light chain (NfL), age, and baseline cognition. Within amyloid-positive AD dementia, plasma miR-214-3p identified rapidly progressive disease and substantially improved prognostic discrimination beyond conventional plasma biomarkers. Longitudinally, declining NCKAP1 and increasing plasma miR-214-3p tracked the rate of cognitive deterioration, whereas plasma p-tau217, GFAP, and NfL changed over time but did not track disease tempo. DISCUSSION: Patient-derived iMG profiling identifies microglial phagocytic dysfunction as a complementary functional dimension of AD progression beyond conventional plasma biomarkers. Longitudinal microglial dynamics tracked disease tempo more closely than conventional plasma pathology markers and may help interpret biological-clinical discordance, supporting biologically informed staging, prognosis, and patient stratification in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.